ORBi: Franchimont N. - Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease

Reference : Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Rheumatology Human health sciences : Gastroenterology & hepatology Human health sciences : Pharmacy, pharmacology & toxicology
	To cite this reference:	http://hdl.handle.net/2268/25035

Title :	Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
Language :	English
Author, co-author :	Franchimont, N. [> > > >]
	Putzeys, V. [> > > >]
	Collette, Julien [Centre Hospitalier Universitaire de Liège - CHU > > Chimie médicale >]
	Vermeire, S. [> > > >]
	Rutgeerts, P. [> > > >]
	De Vos, M. [> > > >]
	Van Gossum, A. [> > > >]
	Franchimont, D. [> > > >]
	Fiasse, R. [> > > >]
	Pelckmans, P. [> > > >]
	Malaise, Michel [Université de Liège - ULg > Département des sciences cliniques > Rhumatologie >]
	Belaiche, Jacques [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie]
	Louis, Edouard [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie >]
Publication date :	15-Sep-2004
Journal title :	Alimentary Pharmacology & Therapeutics
Publisher :	Blackwell Publishing Ltd
Volume :	20
Issue/season :	6
Pages :	607-614
Audience :	International
ISSN :	0269-2813
City :	Oxford
Abstract :	[en] BACKGROUND: Crohn's disease is associated with low bone mineral density and altered bone metabolism. AIM: To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab. METHODS: We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group. RESULTS: Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14-51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30-61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter. CONCLUSION: Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.
Target :	Researchers ; Professionals
Permalink :	http://hdl.handle.net/2268/25035
DOI :	10.1111/j.1365-2036.2004.02152.x

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	Rapid improvement of bone metabolism... 2004.pdf		Publisher postprint	3.44 MB	Request copy
Open access	Rapid improvement of bone metabolism...- Aliment Pharmacol Ther 2004 20 607-614.pdf		Author postprint	210.82 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5